Candidiasis Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028 Segmented By Route of Administration (Injection, Ointment, Oral), By Drug Type (Polyene, Azole, Echinocandin, Other), By Anatomy Type (Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis), By End-User (Hospitals and Clinics, Retail Pharmacies, Other), By Region, Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description


Forecast Period

2018-2028

Market Size (2023)

USD 1.51 billion

CAGR (2023-2028)

5.15%

Fastest Growing Segment

Oral Segment

Largest Market

North America


Market Overview

Global Candidiasis Therapeutics Market has valued at USD 1.51 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.29% through 2028. Candidiasis, a fungal infection caused primarily by Candida species, has become a significant global healthcare concern. The Global Candidiasis Therapeutics Market, valued at billions of dollars, addresses the demand for effective treatments for this widespread infection.

Candidiasis affects individuals of all ages, from neonates to the elderly. The infection can manifest in various forms, including oral thrush, vaginal candidiasis, esophageal candidiasis, and invasive candidiasis. It is particularly prevalent in immunocompromised individuals, such as those with HIV/AIDS, cancer patients undergoing chemotherapy, and organ transplant recipients. Additionally, the overuse of antibiotics has contributed to the rise in candidiasis cases.

Key Market Drivers

The Rising Incidence of Candidiasis

Candidiasis, caused primarily by the Candida species of fungi, is a common fungal infection affecting humans. What's alarming is the increasing prevalence of this infection. Several factors contribute to this surge in incidence. The widespread use of antibiotics, which disrupt the balance of natural microflora in the body, is a key factor. Additionally, the aging population and the growing number of immunocompromised individuals, such as those with HIV/AIDS or undergoing chemotherapy, are more susceptible to candidiasis. This rising incidence of candidiasis has a direct impact on the pharmaceutical industry. As the infection becomes more widespread, the demand for effective therapeutics and treatments also grows. Pharmaceutical companies recognize this expanding market and are investing heavily in research and development to create innovative drugs and therapies to combat candidiasis. This heightened focus on candidiasis research has led to the development of more targeted and efficient treatment options.

Technological Advancements in Diagnosis

One of the groundbreaking advancements in candidiasis diagnosis and treatment is the adoption of precision medicine. This approach tailor’s treatment to the specific genetic makeup of patients. Molecular diagnostics and genetic testing now allow healthcare providers to identify the exact strain of Candida causing the infection. This level of precision enables doctors to prescribe treatments that are more likely to be effective, reducing the trial-and-error approach to therapy selection. Technological innovations like telemedicine and remote monitoring have streamlined the diagnosis and management of candidiasis. Patients can now consult with healthcare professionals and receive treatment recommendations without the need for physical visits to medical facilities. This not only improves patient convenience but also enhances the overall efficiency of healthcare delivery, particularly for those with chronic or recurring candidiasis.

Globalization of Healthcare

The globalization of healthcare has made candidiasis therapeutics more accessible worldwide. Patients from different regions can now access advanced treatments and medications, reducing geographical disparities in healthcare. This accessibility has not only benefited patients but has also intensified competition among pharmaceutical companies, resulting in more affordable treatment options. Globalization has facilitated collaborative research efforts among scientists and healthcare professionals from various corners of the world. Researchers with diverse expertise are coming together to find innovative solutions to combat candidiasis. This cross-border exchange of knowledge accelerates the development of candidiasis therapies, potentially leading to breakthrough treatments.

Regulatory Initiatives and Funding

Government bodies and non-profit organizations recognize the public health significance of candidiasis. Consequently, they have increased funding for research and development in this field. This financial support serves as a strong incentive for pharmaceutical companies to invest in candidiasis therapeutics, thereby expediting the drug development process. Regulatory agencies have also played a pivotal role in driving the growth of candidiasis therapeutics. They have introduced expedited approval processes for drugs and treatments that show promise in combating candidiasis. These streamlined approval processes reduce the time it takes for new therapies to reach patients in need, ensuring quicker access to effective treatments.The growth of the Global Candidiasis Therapeutics market is significantly driven by the rising incidence of candidiasis, technological advancements in diagnosis, globalization of healthcare, and regulatory initiatives and funding. These factors collectively create a dynamic landscape where pharmaceutical innovation, precision medicine, global accessibility, and supportive policies converge to improve the outlook for candidiasis patients and drive the expansion of the therapeutics market.

 

Download Free Sample Report

Key Market Challenges

Antifungal Resistance

Antifungal resistance is a significant and growing concern in the treatment of candidiasis. Over the years, due to the widespread use of antifungal medications, some Candida strains have developed resistance to commonly used drugs. This resistance makes it increasingly difficult to treat infections effectively. The emergence of antifungal resistance poses a major challenge to the growth of the candidiasis therapeutics market. It limits the effectiveness of existing medications, leading to treatment failures and a need for alternative, often more expensive, drugs. Developing new antifungal agents is a time-consuming and costly process, which can hinder market growth. Additionally, healthcare providers may be forced to resort to more aggressive and potentially toxic treatments when standard antifungals fail, leading to concerns about patient safety.

Diagnosis and Identification Challenges

Accurate and timely diagnosis of candidiasis is crucial for effective treatment. However, diagnosing candidiasis can be challenging due to the diverse clinical presentations of the infection. Symptoms can mimic other conditions, leading to misdiagnosis or delayed diagnosis. Moreover, identifying the specific Candida species responsible for an infection is essential for targeted therapy, but traditional diagnostic methods may not provide rapid species-level identification. These diagnostic challenges can slow down the growth of the candidiasis therapeutics market in several ways. Delayed or incorrect diagnoses can lead to prolonged infections, more severe disease, and increased healthcare costs. It can also result in unnecessary use of broad-spectrum antifungals, contributing to antifungal resistance. To address these challenges, there is a need for improved diagnostic technologies that can quickly and accurately identify Candida species and provide actionable information for healthcare providers.

Economic and Access Barriers

Access to candidiasis therapeutics is not uniform across regions and populations. In some parts of the world, particularly in low- and middle-income countries, access to advanced antifungal medications may be limited due to economic constraints. The high cost of newer antifungal drugs can pose a significant barrier to treatment for those who need it most. Economic and access barriers can hinder the growth of the candidiasis therapeutics market by limiting the market reach of pharmaceutical companies. The potential for profit in low-income regions may not be as attractive to these companies, which can slow down the development and distribution of new therapies. Additionally, it perpetuates health disparities, as individuals in resource-limited settings may face greater challenges in accessing timely and effective treatment Antifungal resistance, diagnosis and identification challenges, and economic and access barriers are three major challenges that can impede the growth of the Global Candidiasis Therapeutics market. Addressing these challenges requires collaborative efforts among pharmaceutical companies, healthcare providers, regulatory agencies, and global health organizations to develop innovative therapies, improve diagnostics, and ensure equitable access to treatment for all individuals affected by candidiasis. Overcoming these hurdles is essential to advance the field of candidiasis therapeutics and enhance patient outcomes worldwide.

Key Market Trends

Antifungal Drug Development and Innovation

One prominent trend in the Global Candidiasis Therapeutics market is the continuous development and innovation of antifungal drugs. With the rise of antifungal resistance and the need for more effective treatments, pharmaceutical companies are investing in research and development to create novel antifungal agents. These drugs aim to combat drug-resistant Candida strains and provide improved therapeutic options. Another innovation in the field is the exploration of combination therapies. Researchers are investigating the use of multiple antifungal drugs in tandem to enhance treatment outcomes. Combination therapies can target different aspects of fungal growth and reduce the likelihood of resistance development. This trend reflects a shift towards more personalized and effective treatment approaches.

Precision Medicine and Personalized Treatment

The trend towards precision medicine has also reached the Global Candidiasis Therapeutics market. Genetic testing and molecular diagnostics are increasingly being used to identify the specific Candida species causing an infection and assess its susceptibility to different antifungal agents. This information allows healthcare providers to tailor treatment regimens to the individual patient, improving treatment efficacy and reducing the risk of resistance. Precision medicine has led to the development of individualized treatment plans. Healthcare providers can now select the most appropriate antifungal drug, dose, and duration of treatment based on the patient's genetic profile and the characteristics of the Candida infection. This trend represents a significant advancement in optimizing patient care and outcomes.

Telemedicine and Digital Health Solutions

The integration of telemedicine and digital health solutions is transforming how candidiasis is diagnosed and managed. Patients can now access remote consultations with healthcare providers, allowing for quicker diagnoses and treatment recommendations without the need for in-person visits. This approach is especially valuable for patients with chronic or recurrent candidiasis. Digital health solutions are improving access to candidiasis therapeutics. Patients in remote or underserved areas can benefit from telemedicine consultations, ensuring they receive timely care. Furthermore, digital platforms are being used to educate patients about candidiasis prevention and management, enhancing overall healthcare accessibility.

 

The Global Candidiasis Therapeutics market is experiencing significant trends in antifungal drug development and innovation, the adoption of precision medicine and personalized treatment approaches, and the integration of telemedicine and digital health solutions.

Segmental Insights

Route of Administration Insights

Based on the category of Route of Administration, the oral segment emerged as the dominant player in the global market for Candidiasis Therapeutics in 2022. Oral medications are generally more straightforward to administer compared to other routes, such as intravenous or intramuscular. Patients can take oral antifungal drugs with a glass of water, making it a convenient choice for both healthcare providers and patients.

Oral medications are often preferred because they tend to have higher patient compliance rates. Patients are more likely to adhere to treatment regimens when they involve simple oral dosing. This is crucial for the effective management of candidiasis, which often requires a prolonged course of treatment. Oral antifungal therapy allows for outpatient treatment, reducing the need for hospitalization. This is particularly important for candidiasis patients who have milder or uncomplicated infections. Outpatient treatment is cost-effective and less disruptive to patients' daily lives. Oral medications are more widely accessible, even in remote or resource-limited areas. This accessibility ensures that a larger portion of the population can access treatment for candidiasis, contributing to the dominance of the oral segment in the market. The oral segment offers a wide variety of drug formulations, including tablets, capsules, and liquid suspensions. This variety allows healthcare providers to select the most suitable form for individual patients, taking into consideration factors such as age, swallowing ability, and preference. These factors are expected to drive the growth of this segment.

Drug Type Insights

Based on the category of Drug Type, the azole segment emerged as the dominant player in the global market for Candidiasis Therapeutics in 2022. Azole antifungal drugs, such as fluconazole, itraconazole, and voriconazole, exhibit broad-spectrum activity against various Candida species. They are effective against both common and less common strains of Candida, making them versatile choices for candidiasis treatment.

Azole antifungals have demonstrated clinical efficacy in the treatment of candidiasis. They are often the first-line treatment for many types of Candida infections, including oral thrush, esophageal candidiasis, and invasive candidiasis, due to their proven effectiveness. Azole drugs are available in both oral and intravenous formulations, providing flexibility in administration. Patients with mild candidiasis can take oral tablets or liquid suspensions, while those with severe infections can receive intravenous formulations, ensuring that treatment options are suitable for a wide range of patients. Azole antifungals can be used in both outpatient and inpatient settings. This versatility allows healthcare providers to tailor treatment plans to the severity of the infection and the patient's clinical status, contributing to their widespread use. Azole antifungals are often prescribed prophylactically in high-risk patients, such as those undergoing chemotherapy, organ transplantation, or major surgeries. Prophylactic use helps prevent Candida infections, especially in immunocompromised individuals. These factors collectively contribute to the growth of this segment.

Anatomy Type Insight

Based on the category of Anatomy Type, the oral candidiasis segment emerged as the dominant player in the global market for Candidiasis Therapeutics in 2022. Oral candidiasis, also known as oral thrush, is one of the most common manifestations of candidiasis. It occurs frequently in both immunocompromised and immunocompetent individuals. Its high prevalence makes it a significant segment within the candidiasis market.

Oral candidiasis typically presents with visible and uncomfortable symptoms, including white or creamy patches on the tongue, inner cheeks, and other parts of the mouth. These visible signs often prompt individuals to seek medical attention, increasing the diagnosis rate and treatment demand. Diagnosis of oral candidiasis is relatively straightforward, often based on visual examination by healthcare providers. The simplicity of diagnosis allows for prompt identification and treatment of this form of candidiasis. Oral candidiasis can significantly impact a patient's quality of life. Symptoms such as pain, burning sensations, and difficulty swallowing can be debilitating. Patients are highly motivated to seek treatment to alleviate these discomforts. Several common risk factors, such as immunosuppression, diabetes, and the use of corticosteroids or antibiotics, increase the susceptibility to oral candidiasis. As these risk factors are prevalent worldwide, the demand for treatment remains high.

End-User Insight

Based on the category of End-User, the Hospital & Clinics segment emerged as the dominant player in the global market for Candidiasis Therapeutics in 2022. Hospitals and clinics are equipped with specialized medical professionals, including infectious disease specialists and dermatologists, who are well-trained in diagnosing and treating candidiasis. Patients often seek these healthcare facilities for expert care.

Hospitals and clinics have access to advanced diagnostic facilities, such as microscopy, culture testing, and molecular diagnostics. These facilities enable accurate and timely diagnosis of candidiasis, leading to effective treatment. Candidiasis can range from mild to severe, with invasive candidiasis being a potentially life-threatening condition. Hospitals are equipped to handle severe cases and provide critical care when necessary. This makes them the preferred choice for patients with serious candidiasis infections. Some candidiasis cases require inpatient treatment, particularly when the infection has spread to other parts of the body or when patients have underlying health conditions. Hospitals offer the infrastructure and resources needed for inpatient care. Intravenous antifungal medications may be required for severe candidiasis cases. Hospitals have the capability to administer intravenous therapy, ensuring that patients receive the appropriate treatment route. Patients with compromised immune systems, such as those with HIV/AIDS, organ transplant recipients, or cancer patients undergoing chemotherapy, are at higher risk of candidiasis. These individuals often receive treatment in hospitals and clinics, where their complex healthcare needs can be addressed.

Regional Insights

North America emerged as the dominant player in the global Candidiasis Therapeutics market in 2022, holding the largest market share in terms of value. This dominance is primarily attributed to the region's well-established healthcare infrastructure, high prevalence of candidiasis in various forms, and significant investments in research and development. The U.S. has a substantial market share due to its advanced healthcare facilities, widespread access to antifungal treatments, and a large patient population. The North American region experiences a consistent demand for candidiasis therapeutics due to its aging population, high rates of immunocompromised patients, and the presence of major pharmaceutical companies engaged in antifungal drug development. Additionally, increased awareness and early diagnosis contribute to market growth.

The Asia-Pacific region, including countries like China and India, is experiencing rapid growth in the candidiasis therapeutics market. This growth is driven by factors such as a large and aging population, rising awareness of fungal infections, and improvements in healthcare infrastructure. As these countries continue to develop their healthcare systems, access to candidiasis treatment options is expanding. The Asia-Pacific region has seen a surge in immunocompromised patients due to conditions like HIV/AIDS and an increase in organ transplant procedures. This has led to a higher incidence of candidiasis. Additionally, pharmaceutical companies are increasingly focusing on this region, conducting clinical trials and introducing antifungal medications, contributing to its status as the fastest-growing market.


Download Free Sample Report

Recent Developments

  • On August 4, 2023, Basilea announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its antifungal drug ceftobiprole for the treatment of complicated urinary tract infections (cUTIs) caused by Escherichia coli (E. coli). Ceftobiprole is a cephalosporin antibiotic that is active against a wide range of bacteria, including E. coli.
  • On July 20, 2023, Astellas announced that it has received a breakthrough therapy designation from the US Food and Drug Administration (FDA) for its new drug asfotase alfa for the treatment of hypophosphatasia. Hypophosphatasia is a rare genetic disorder that affects the bones and teeth. Asfotase alfa is a new enzyme replacement therapy that is active against hypophosphatasia.   
  • On June 21, 2023, SCYNEXIS announced that it has achieved a first development milestone of $25 million under its exclusive license agreement with GSK for ibrexafungerp. The milestone payment follows the achievement of a development goal for the Phase 3 MARIO study for ibrexafungerp in invasive candidiasis.

Key Market Players

  • Basilea Pharmaceutica Ltd
  • Astellas Pharma Inc.
  • SCYNEXIS, Inc.
  • NovaDigm Therapeutics
  • Mycovia Pharmaceuticals, Inc.
  • Cidara Therapeutics Inc.
  • Pfizer Inc.
  • Bayer AG
  • Viatris Inc.
  • Novabiotics Limited

 By Route of Administration

By Drug Type

By Anatomy Type

By End-User

By Region
  • Injection
  • Ointment
  • Oral
  •  
  • Polyene
  • Azole
  • Echinocandin
  • Other
  • Oral Candidiasis
  • Vulvovaginal Candidiasis
  • Cutaneous Candidiasis
  • Invasive Candidiasis
  • Systemic Candidiasis
  • Hospitals and Clinics
  • Retail Pharmacies
  • Other
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Candidiasis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Candidiasis Therapeutics Market, By Route of Administration:

o   Injection

o   Ointment

o   Oral

  • Candidiasis Therapeutics Market, By Drug Type:

o   Polyene

o   Azole

o   Echinocandin

o   Other

  • Candidiasis Therapeutics Market, By Anatomy Type:

o   Oral Candidiasis

o   Vulvovaginal Candidiasis

o   Cutaneous Candidiasis

o   Invasive Candidiasis

o   Systemic Candidiasis

  • Candidiasis Therapeutics Market, By End-User:

o   Hospitals and Clinics

o   Retail Pharmacies

o   Other

  • Candidiasis Therapeutics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

§  Turkey

§  Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Candidiasis Therapeutics Market.

Available Customizations:

Global Candidiasis Therapeutics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Candidiasis Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Candidiasis Therapeutics Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Route of Administration (Injection, Ointment, Oral)

5.2.2.    By Drug Type (Polyene, Azole, Echinocandin, Other)

5.2.3.    By Anatomy Type (Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis)

5.2.4.    By End-User (Hospitals and Clinics, Retail Pharmacies, Other)

5.2.5.    By Region

5.2.6.    By Company (2022)

5.3.  Market Map

6.    North America Candidiasis Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Route of Administration

6.2.2.    By Drug Type

6.2.3.    By Anatomy Type

6.2.4.    By End-User

6.2.5.    By Country

6.3.  North America: Country Analysis

6.3.1.    United States Candidiasis Therapeutics Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Route of Administration

6.3.1.2.2.           By Drug Type

6.3.1.2.3.           By Anatomy Type

6.3.1.2.4.           By End-User

6.3.2.    Canada Candidiasis Therapeutics Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Route of Administration

6.3.2.2.2.           By Drug Type

6.3.2.2.3.           By Anatomy Type

6.3.2.2.4.           By End-User

6.3.3.    Mexico Candidiasis Therapeutics Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Route of Administration

6.3.3.2.2.           By Drug Type

6.3.3.2.3.           By Anatomy Type

6.3.3.2.4.           By End-User

7.    Europe Candidiasis Therapeutics Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Route of Administration

7.2.2.    By Drug Type

7.2.3.    By Anatomy Type

7.2.4.    By End-User

7.3.  Europe: Country Analysis

7.3.1.    Germany Candidiasis Therapeutics Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Route of Administration

7.3.1.2.2.           By Drug Type

7.3.1.2.3.           By Anatomy Type

7.3.1.2.4.           By End-User

7.3.2.    United Kingdom Candidiasis Therapeutics Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Route of Administration

7.3.2.2.2.           By Drug Type

7.3.2.2.3.           By Anatomy Type

7.3.2.2.4.           By End-User

7.3.3.    Italy Candidiasis Therapeutics Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecasty

7.3.3.2.1.           By Route of Administration

7.3.3.2.2.           By Drug Type

7.3.3.2.3.           By Anatomy Type

7.3.3.2.4.           By End-User

7.3.4.    France Candidiasis Therapeutics Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Route of Administration

7.3.4.2.2.           By Drug Type

7.3.4.2.3.           By Anatomy Type

7.3.4.2.4.           By End-User

7.3.5.    Spain Candidiasis Therapeutics Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Route of Administration

7.3.5.2.2.           By Drug Type

7.3.5.2.3.           By Anatomy Type

7.3.5.2.4.           By End-User

8.    Asia-Pacific Candidiasis Therapeutics Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Route of Administration

8.2.2.    By Drug Type

8.2.3.    By Anatomy Type

8.2.4.    By End-User

8.3.  Asia-Pacific: Country Analysis

8.3.1.    China Candidiasis Therapeutics Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Route of Administration

8.3.1.2.2.           By Drug Type

8.3.1.2.3.           By Anatomy Type

8.3.1.2.4.           By End-User

8.3.2.    India Candidiasis Therapeutics Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Route of Administration

8.3.2.2.2.           By Drug Type

8.3.2.2.3.           By Anatomy Type

8.3.2.2.4.           By End-User

8.3.3.    Japan Candidiasis Therapeutics Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Route of Administration

8.3.3.2.2.           By Drug Type

8.3.3.2.3.           By Anatomy Type

8.3.3.2.4.           By End-User

8.3.4.    South Korea Candidiasis Therapeutics Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.           By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.           By Route of Administration

8.3.4.2.2.           By Drug Type

8.3.4.2.3.           By Anatomy Type

8.3.4.2.4.           By End-User

8.3.5.    Australia Candidiasis Therapeutics Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.           By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.           By Route of Administration

8.3.5.2.2.           By Drug Type

8.3.5.2.3.           By Anatomy Type

8.3.5.2.4.           By End-User

9.    South America Candidiasis Therapeutics Market Outlook

9.1.  Market Size & Forecast

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Route of Administration

9.2.2.    By Drug Type

9.2.3.    By Anatomy Type

9.2.4.    By End-User

9.3.  South America: Country Analysis

9.3.1.    Brazil Candidiasis Therapeutics Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Route of Administration

9.3.1.2.2.           By Drug Type

9.3.1.2.3.           By Anatomy Type

9.3.1.2.4.           By End-User

9.3.2.    Argentina Candidiasis Therapeutics Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Route of Administration

9.3.2.2.2.           By Drug Type

9.3.2.2.3.           By Anatomy Type

9.3.2.2.4.           By End-User

9.3.3.    Colombia Candidiasis Therapeutics Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Route of Administration

9.3.3.2.2.           By Drug Type

9.3.3.2.3.           By Anatomy Type

9.3.3.2.4.           By End-User

10. Middle East and Africa Candidiasis Therapeutics Market Outlook

10.1.   Market Size & Forecast        

10.1.1. By Value

10.2.   Market Share & Forecast

10.2.1. By Route of Administration

10.2.2. By Drug Type

10.2.3. By Anatomy Type

10.2.4. By End-User

10.3.   MEA: Country Analysis

10.3.1. South Africa Candidiasis Therapeutics Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Route of Administration

10.3.1.2.2.         By Drug Type

10.3.1.2.3.         By Anatomy Type

10.3.1.2.4.         By End-User

10.3.2. Saudi Arabia Candidiasis Therapeutics Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Route of Administration

10.3.2.2.2.         By Drug Type

10.3.2.2.3.         By Anatomy Type

10.3.2.2.4.         By End-User

10.3.3. UAE Candidiasis Therapeutics Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Route of Administration

10.3.3.2.2.         By Drug Type

10.3.3.2.3.         By Anatomy Type

10.3.3.2.4.         By End-User

11. Market Dynamics

11.1.   Drivers & Challenges

12. Market Trends & Developments

12.1.   Recent Developments

12.2.   Product Launches

12.3.   Mergers & Acquisitions

13. Global Candidiasis Therapeutics Market: SWOT Analysis

14. Competitive Landscape

14.1.   Business Overview

14.2.   Drug Type Offerings

14.3.   Recent Developments

14.4.   Key Personnel

14.5.   SWOT Analysis

14.5.1. Basilea Pharmaceutica Ltd

14.5.2. Astellas Pharma Inc.

14.5.3. SCYNEXIS, Inc.

14.5.4. NovaDigm Therapeutics

14.5.5. Mycovia Pharmaceuticals, Inc.

14.5.6. Cidara Therapeutics Inc.

14.5.7. Pfizer Inc.

14.5.8. Bayer AG

14.5.9. Viatris Inc.

14.5.10.              Novabiotics Limited

15. Strategic Recommendations

About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Candidiasis Therapeutics Market was estimated to be USD 1.51 billion in 2022.

down-arrow

Basilea Pharmaceutica Ltd, Astellas Pharma Inc, SCYNEXIS, Inc., NovaDigm Therapeutics, Mycovia Pharmaceuticals, Inc., Cidara Therapeutics Inc., Pfizer Inc., Bayer AG, Viatris Inc., Novabiotics Limited are the major key players in the Global Candidiasis Therapeutics Market.

down-arrow

Economic and access and diagnostics and identification challenges are the major challenges which can slow down the growth of Global Candidiasis Therapeutics Market.

down-arrow

Globalization of healthcare, increasing prevalence of candidiasis and Technological Advancements in Diagnosis are the major drivers for the Global Candidiasis Therapeutics Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Candidiasis Therapeutics Market to Grow with a CAGR of 6.29% through 2028

Sep, 2023

Increase in the incidence of candidiasis and increase in the Telemedicine and Remote Monitoring is expected to drive the Global Candidiasis Therapeutics Market growth in the forecast period, 2024-202

Why Choose Us